TCM
PTGX icon

Tekla Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Tekla Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-122,271
Closed -$1.33M – 184
2022
Q4 		$1.33M Buy
+122,271
New +$1.03M 0.05% 127
2022
Q3 		– Sell
-122,271
Closed -$967K – 179
2022
Q2 		$967K Hold
122,271
– – 0.04% 135
2022
Q1 		$2.9M Buy
122,271
+21,234
+21% +$598K 0.1% 110
2021
Q4 		$3.46M Buy
101,037
+14,800
+17% +$468K 0.11% 113
2021
Q3 		$1.53M Buy
+86,237
New +$3.68M 0.05% 142
2019
Q3 		– Sell
-121,341
Closed -$1.47M – 195
2019
Q2 		$1.47M Sell
121,341
-56,084
-32% -$620K 0.06% 146
2019
Q1 		$2.23M Sell
177,425
-19,713
-10% -$174K 0.09% 127
2018
Q4 		$1.33M Sell
197,138
-21,904
-10% -$174K 0.06% 148
2018
Q3 		$2.25M Hold
219,042
– – 0.08% 146
2018
Q2 		$1.47M Hold
219,042
– – 0.06% 148
2018
Q1 		$1.88M Buy
219,042
+136,220
+164% +$2.57M 0.07% 139
2017
Q4 		$1.72M Buy
82,822
+75,000
+959% +$1.33M 0.07% 133
2017
Q3 		$138K Buy
+7,822
New +$108K ﹤0.01% 150

Other funds holding PTGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tekla Capital Management's PTGX Position: Q1 2023 in Review

Tekla Capital Management sold out of Protagonist Therapeutics (PTGX) in Q1 2023, closing a stake of 122,271 shares — an estimated $1.33M sold.

Tekla Capital Management first reported a position in PTGX in Q3 2017 and held it in 13 quarters. The position peaked at $3.46M in Q4 2021. 137 funds tracked by Wall St. Rank hold PTGX as of Q1 2023.

  • Tekla Capital Management reported no remaining Protagonist Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Tekla Capital Management sold 122,271 Protagonist Therapeutics shares in Q1 2023, an estimated $1.33M.
  • Tekla Capital Management first reported a position in Protagonist Therapeutics in Q3 2017 and held it in 13 quarters.
  • Tekla Capital Management's Protagonist Therapeutics position peaked at $3.46M in Q4 2021.
  • 137 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2023.

Based on Tekla Capital Management's 13F filing for Q1 2023, filed 10 May 2023.